MONTREAL, July 03, 2020 (GLOBE NEWSWIRE) — Further to its news release dated May 15, 2020 announcing the entering into of a binding letter of intent, Komet Resources Inc. (“Komet” or the “Company”; TSX-V: KMT) is pleased to announce that it has closed, on July 2, 2020 (the “Closing Date”) its previously announced transaction relating to the sale of all of the issued and outstanding shares of its wholly owned subsidiary Komet Mali SARL (“Komet Mali”), which owns the Dabia Sud project, to RosCan Gold Corporation (“RosCan“; TSX-V: ROS).

The disposition price was CAD $ 3.2 million. Komet received on Closing Date CAD $1.6 million in cash and an aggregate of 4,060,336 common shares of RosCan, each such common share having a deemed issuance value of CAD $0.394, representing the 5-day volume weighted average price of RosCan’s common shares as of the trading day prior to the Closing Date.

RosCan shares issued in the transaction are subject to a voluntary hold period for 6 months after the Closing Date. Komet has entered into a voting trust agreement with RosCan pursuant to which it has agreed to vote the issued RosCan shares in favour of management’s recommendations for a period of 12 months.

Investor Relations/information :

Mr. Robert Wares, Chairman and interim President:  514-951-4235 / r.wares@kometgold.com

More information about the Corporation is available at: http://kometgold.com.

Forward-looking Statements

This press release contains statements that may constitute “forward-looking information” or “forward-looking statements” as set out within the context of security law. This forward-looking information is subject to many risks and uncertainties, some of which are beyond Komet’s control. The actual results or conclusions may differ considerably from those that have been set out, or intimated, in this forward-looking information. There are many factors which may cause such disparity, especially the instability of metal market prices, the results of fluctuations in foreign currency exchange rates or in interest rates, poorly estimated resources, environmental risks (stricter regulations), unforeseen geological situations, unfavourable extraction conditions, political risks brought on by mining in developing countries, regulatory and governmental policy changes (laws and policies), failure to obtain the requisite permits and approvals from government bodies, or any other risk relating to mining and development. There is no guarantee that the circumstances anticipated in this forward-looking information will occur, or if they do occur, how they will benefit Komet. The forward-looking information is based on the estimates and opinions of Komet’s management at the time of the publication of the information and Komet does not assume any obligation to make public updates or modifications to any of the forward-looking statements, whether as a result of new information, future events, or any other cause, except if it is required by securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Frank Czworka appointed SVP, Global Sales

Brian Webb promoted to SVP, Manufacturing

GAITHERSBURG, Md., July 02, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, Manufacturing, with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates.

“Frank’s extensive commercial and sales expertise will be invaluable to Novavax’ transformation into a commercial stage organization,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “Brian has been instrumental in the recent expansion and alignment of our manufacturing capabilities and supply partnerships. I am confident that the company will benefit greatly from their mutual expertise as we advance our efforts to bring NVX‑CoV2373 and NanoFlu to market.”

Mr. Czworka brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as Vice President, Global Customer Engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the University of Central Florida.

“This is an exciting time to join Novavax, with much to be accomplished as we advance our COVID-19 candidate and prepare the regulatory submission for NanoFlu,” said Mr. Czworka. “I’m excited to contribute to the team so that we can positively impact the lives of patients and reduce the global burden of these infectious diseases.”

Mr. Webb joined Novavax in May 2014 with responsibility for internal and external manufacturing. Prior to joining Novavax, Mr. Webb held numerous operational leadership roles at GlaxoSmithKline and Human Genome Sciences where he had the opportunity to take multiple products from early clinical stage through licensure and launch. He received a bachelor of science degree in biology from Salisbury University and a master of science degree in biotechnology from Johns Hopkins University.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Forward-Looking Statements

Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products, including statements regarding the manufacturing of vaccine antigen dose amounts and timing, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading “Risk Factors” in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Contacts:

Investors
Novavax, Inc.
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659

LOS ANGELES, July 02, 2020 (GLOBE NEWSWIRE) — Imperial Capital Group, LLC (“Imperial Capital”), announced today that Simon Mullaly has returned to the markets to launch a European Private Credit Group in which he will serve as Head Trader.  The European Private Credit Group will source private European credit investment opportunities for Imperial Capital’s institutional investors in both Europe and the US.

“We believe that Simon is rejoining the market at the opportune time when there is an increasing appetite for special situations trading in both Europe and the US,” said Tim Sullivan, President of Imperial Capital, LLC. “The addition of Simon to head a dedicated European Private Credit effort affirms the Company’s vision to expand our existing credit sales & trading franchise into non-cusip trading solutions for our clients.”

Simon Mullaly joins Imperial Capital as a Managing Director and Head of the European Private Credit Trading Group.  He will be based in Stamford, CT.  Previously, Mr. Mullaly was the founder and CEO of Yorvik Partners, a European based credit brokerage firm that specialized in distressed debt before being acquired by Sterne Agee in late 2013.  Prior to founding Yorvik, Mr. Mullaly managed trading desks for Deutsche Bank, AG and Lehman Brothers in London.  Mr. Mullaly earned an MBA from The Wharton School at the University of Pennsylvania and a BSc at Nottingham Trent University.

“I am excited to join Imperial Capital’s well-established fixed income platform that includes bespoke research,” said Simon Mullaly.  “I believe that we can leverage Imperial Capital’s platform to grow a Private European Credit group that complements the growth of private debt in Europe as a credible asset class that is systemically changing and here to stay.”

About Imperial Capital, LLC

Imperial Capital, LLC is a full-service investment bank offering a uniquely integrated platform of comprehensive services to institutional investors and middle market companies. We offer sophisticated sales and trading services to institutional investors and a wide range of investment banking advisory, capital markets and restructuring services to middle market corporate clients. Paired with our proprietary research and sales & trading desk analysis, we provide investment analysis across an issuer’s capital structure, including bank loans, debt securities, the hybrid/bank capital marketplace (through our ELP Framework), post-reorganization equities, special situations claims and listed and unlisted equities. Our comprehensive and integrated service platform, expertise across the global capital structure, and deep industry sector knowledge enable us to provide clients with research driven ideas, superior advisory services, and trade execution. We are quick to identify opportunities under any market conditions and we have a proven track record of offering creative, proprietary solutions to our clients. Imperial Capital, LLC has three principal businesses: Investment Banking, Institutional Sales & Trading and Institutional Research. More information about Imperial Capital, LLC can be found at www.imperialcapital.com.

For more information regarding Imperial Capital, please contact:
Mark Martis
+1 310 246 3674
mmartis@imperialcapital.com

About Imperial Capital (International), LLP

Imperial Capital International, founded in 2011, is an affiliate of Imperial Capital, LLC with an office in central London.  Complementing Imperial Capital’s existing corporate credit sales and trading franchise, Imperial Capital International expanded the Imperial Capital franchise into the EEA.  The company focuses on the entire credit spectrum and takes a full capital structure research approach to supplement sales and trading services to its European institutional clients.

For more information regarding Imperial Capital (International), LLP, please contact:
Emma McClintock
+ 44 (0) 207 650 5429
emcclintock@imperialcapital.com

Helsinn Group and MEI Pharma Discontinue the Phase 3 Study with Pracinostat in AML after Completing Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of the ongoing Phase 3 study of pracinostat in combination with azacitidine in patients with AML who are unfit to receive standard intensive chemotherapy, undertaken by the study Independent Data Monitoring Committee (“IDMC”), has demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group. Based on the outcome of the interim analysis, the decision was made to discontinue the recruitment of patients and end the study. The decision was based on a lack of efficacy and not on safety concerns. Pending further evaluation, patients currently enrolled in other pracinostat studies will continue treatment.

About AML

Acute Myeloid Leukemia (AML) is a disorder of the blood and bone marrow caused by the uncontrolled proliferation of an abnormal hematopoietic cell of myeloid lineage. This results in a high circulating number of immature blood cells and replacement of normal bone marrow by malignant cells. AML has various subtypes, which are based on the type of cell from which the leukemia developed. It is typically a disease of older patients, with a median age at diagnosis of 67 years. Whilst the cure rate with intensive chemotherapy for AML patients who are 60 or younger is 35 to 40%, the rate is poor in older patients, typically not exceeding 15%.

About Pracinostat

Pracinostat is an oral histone deacetylase (“HDAC”) inhibitor that is being investigated in combination with azacitidine for the treatment of adults with newly diagnosed acute myeloid leukemia (“AML”) who are unfit for standard intensive chemotherapy. It is also being evaluated in a Phase II study in patients with high or very high-risk myelodysplastic syndromes (“MDS”). The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted Orphan Drug Designation for pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are ≥75 years of age or unfit for intensive chemotherapy. In addition, the FDA has granted Breakthrough Therapy Designation to the combination treatment.

In August 2016, Helsinn and MEI Pharma entered an exclusive license, development and commercialization agreement for pracinostat in AML and other potential indications. The agreement provides that Helsinn is primarily responsible for development and commercialization costs for pracinostat in AML and other indications, including MDS.

Pracinostat is an investigational agent and is not approved for commercial use in the U.S. or any other country worldwide.

About the Helsinn Group

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

Helsinn Group plays an active and central role in promoting social transformation in favor of people and the environment. Corporate social responsibility is at the heart of everything we do which is reinforced in the company’s strategic plan by a commitment to sustainable growth.

To learn more about Helsinn Group please visit www.helsinn.com

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma’s portfolio of drug candidates contains four clinical-stage assets, including ME-401, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U.S. Food and Drug Administration. Each of MEI Pharma’s pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. For more information, please visit www.meipharma.com.

Forward-Looking Statements

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; the impact of the COVID-19 pandemic on our industry and individual companies, including on our counterparties, the supply chain, the execution of our clinical development programs, our access to financing and the allocation of government resources; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

For more information:

Helsinn Group Media Contact:
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Email: Info-hhc@helsinn.com
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo

MEI Pharma

David A. Walsey
VP of IR and Corporate Communications
Tel: 858-369-7104
investor@meipharma.com

Jason I. Spark
Canale Communications for MEI
Tel: 619-849-6005
jason@canalecomm.com

VistaJet

VistaJet Global 7500

Working with leading partners Philips and MedAire to further safeguard all passengers

• The first charter operator to embed the revolutionary Tempus IC2 device within its entire Global fleet;
• Crew can measure and securely transmit vital clinical data in real-time to ground-based medical experts 24/7, anytime, anywhere;
• The innovative medical monitor, integrated with MedAire’s medical team, is the next best thing to having a doctor by your side.

LONDON, July 02, 2020 (GLOBE NEWSWIRE) — VistaJet, the first and only global business aviation company, places the safety, security and wellbeing of its customers and colleagues above all else. To further safeguard those who fly on board its fleet, VistaJet has worked with partners RDT, a Philips company, and MedAire to be the first charter operator to embed Tempus IC2 monitors within their entire Global fleet — granting access to leading medical support anytime, anywhere. Tempus IC2 is a vital signs monitor with integrated telemedicine, designed for use in remote medical emergencies by non-medical experts.

These days, with increased general safety requirements, the value of critical care is becoming more and more prominent, especially for those traveling hours away from quality medical help. Having RDT’s Tempus IC2 monitors on VistaJet Global flights provide reassurance and assistance for passengers and crew on the aircraft. The monitor allows VistaJet crew to measure and transmit vital clinical data and images, alongside real-time voice and video, securely and directly to MedAire’s ground-based medical team 24/7 should they become concerned about their, or a passenger’s, fitness-to-fly for treatment guidance and advice — wherever they are in the world.

Thomas Flohr, VistaJet’s Founder and Chairman, said:
“VistaJet crew now have even more resources to give them and passengers complete peace of mind with every flight. The information from the monitor is seamlessly and confidentially shared with the ground-based medical experts — it is the next best thing to having a doctor by your side and yet another example of VistaJet’s investment into safety and security to protect all those who fly with us on our global infrastructure. All operators with a global program should have this technology available on board.”

VistaJet

Tempus IC2 monitor

Through VistaJet’s secure onboard connection, Tempus IC2 expedites time to care for passengers experiencing medical issues during flight, allowing crew to easily capture important diagnostic information and transmit it to MedAire’s medical advisory service, MedLink, for expert advice and assistance. The direct link to MedAire health experts along with the vital signs data can additionally contribute to the reduction of the personal risks which are often associated with misdiagnosis, avoiding unnecessary and costly medical evacuations or diversions.

Dr Paulo M. Alves, Global Medical Director at MedAire added:
“The parameters available when taking a Tempus call are essentially the same as those one would have in most emergency rooms. Tempus IC2 is invaluable when remotely managing a medical situation, because it gives MedAire’s MedLink doctors the clinical-quality data needed to make a better diagnostic impression.”

MedAire can also assists the ill passenger with obtaining further medical care or prescription medications at the aircraft’s final destination. Should the passengers need treatment not available on board, VistaJet’s end-to-end Operations team will be able to change the flight path or destination based on information from MedAire on suitably equipped and vetted hospitals and the nearest airport to them. All aviation companies have a duty to passengers to provide comprehensive medical back-up and VistaJet’s adoption of the latest medical teleconsultation services will secure a more convenient and timely care, minimizing disruption to travel plans.

For more information on VistaJet’s safety standards and its efforts to help stop the spread of COVID-19, visit: vistajet.com/safety

Information
Jennifer Farquhar | VistaJet | jennifer.farquhar@vistajet.com

About VistaJet
VistaJet is the first and only global business aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.

VistaJet

VistaJet safety on board

VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.

More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/41e26875-45d8-498c-882f-8f5d093f39fb

https://www.globenewswire.com/NewsRoom/AttachmentNg/98e0dc51-0e54-48a9-a08c-58b59e20c2e9

https://www.globenewswire.com/NewsRoom/AttachmentNg/782cd9f4-efeb-4242-9c44-c4672c5b6574